Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 15/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | BLVRB | P30043 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19981240 | 0.93 | LMNA (0.40) | CTSALMNATSHRMAOABLVRB | |
| SCHEMBL19981233 | 0.91 | LMNA (0.44) | CTSALMNATSHRMAOABLVRB | |
| SCHEMBL19981269 | 0.90 | CTSA (0.45) | CTSALMNATSHRSUCNR1KMT2A | |
| SCHEMBL24218494 | 0.90 | LMNA (0.45) | CTSALMNATSHRMAOABLVRB | |
| SCHEMBL18077943 | 0.77 | VSIR (0.48) | CTSA | |
| SCHEMBL19867021 | 0.77 | VSIR (0.48) | CTSA | |
| SCHEMBL19981130 | 0.77 | CTSA (0.41) | CTSALMNATSHR | |
| SCHEMBL19975478 | 0.70 | DPP4 (0.40) | CTSA | |
| SCHEMBL19975480 | 0.70 | DPP4 (0.40) | CTSA | |
| SCHEMBL19867093 | 0.70 | CD274 (0.58) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046904-A1 | COMBINATION OF SMALL MOLECULE INHIBITOR OF THE PD-1/PD-L1 INTERACTION AND ANTI-PD-1 ANTIBODY FOR TREATING CANCER | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| US-20220168268-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2022-06-02 | — | — | US | disclosed |
| EP-3943083-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021052386-A1 | COMBINATION OF SMALL MOLECULE INHIBITOR OF THE PD-1/PD-L1 INTERACTION AND ANTI-PD-1 ANTIBODY FOR TREATING CANCER | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020192570-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | 上海再极医药科技有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2018051254-A1 | CYCLIC SUBSTITUTED-1,2,4-OXADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046904-A1 | COMBINATION OF SMALL MOLECULE INHIBITOR OF THE PD-1/PD-L1 INTERACTION AND ANTI-PD-1 ANTIBODY FOR TREATING CANCER | PDCD1, CD274, PDCD1LG2 | CTSA 3201/4885LMNA 4094/4885TSHR 2208/4885 |
| US-20220168268-A1 | SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME | PDCD1, PDCD1LG2, CD274 | CTSA 3945/4885LMNA 3485/4885TSHR 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.